City

Houston (1)

Milano (1)

Condition

Metastatic Well Differentiated Neuroendocrine Neoplasm (2)

Meningioma (1)

Multiple Endocrine Neoplasia Type 1 (1)

Neuroendocrine Neoplasm (1)

Neuroendocrine Tumors (1)

Somatostatin Positive Neoplastic Cells Present (1)

Von Hippel-Lindau Syndrome (1)

Overall Status

Recruiting (1)

Terminated (1)

Sign in for free

Phase

early phase 1 (1)

phase 2 (1)

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1)

M.D. Anderson Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

cabozantinib (1)

computed tomography (1)

gallium ga 68-edotreotide (1)

lanreotide (1)

positron emission tomography (1)

Study Documents

Intervention Type

drug (2)

procedure (1)

Funder Type

Other (2)

Study Type

Interventional (2)

metastatic well differentiated neuroendocrine neoplasm

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Metastatic Well Differentiated Neuroendocrine Tumor, Neuroendocrine Tumors Trial in Milano (Cabozantinib, Lanreotide)

Recruiting

Metastatic Well Differentiated Neuroendocrine Neoplasm
Neuroendocrine Tumors

Milano, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori

Sep 3, 2021

Meningioma, Metastatic Well Differentiated Neuroendocrine Tumor, Multiple Endocrine Neoplasia Type 1 Trial in Houston (Computed

Terminated

Meningioma
+5 more

Computed Tomography
+2 more

Houston, Texas

M D Anderson Cancer Center

Feb 11, 2021